Clinical Trial Update: Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 [Phase 1, Phase 2]

View source ↗

Summary

A study evaluating the safety and efficacy of Debio 1143, a SMAC mimetic, in solid tumors has completed Phase 1/2 with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• Debio 1143

Snippet

Sponsor: Debiopharm International SA | Conditions: Solid Tumor | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-06-12